 |
|
|
| |
Effect of hepatitis C treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on patient's health-related quality of life: Analysis of Phase 3a and Phase 3b clinical trials
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Sammy Saab1, Darshan Mehta2,3, Stacie Hudgens4, Nathan Grunow4, Yanjun Bao3, Brett Pinsky3
1David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; 2Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA; 3Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA; 4Clinical Outcomes Solutions, Tucson, AZ, USA
|
| |
|
|
|
|
|
